HC Wainwright Issues Pessimistic Estimate for SRTS Earnings

Sensus Healthcare, Inc. (NASDAQ:SRTS) – Equities research analysts at HC Wainwright lowered their Q1 2025 earnings estimates for Sensus Healthcare in a report issued on Monday, February 10th. HC Wainwright analyst Y. Chen now expects that the company will post earnings per share of $0.11 for the quarter, down from their previous estimate of $0.14. HC Wainwright currently has a “Buy” rating and a $12.00 target price on the stock. The consensus estimate for Sensus Healthcare’s current full-year earnings is $0.71 per share. HC Wainwright also issued estimates for Sensus Healthcare’s Q3 2025 earnings at $0.10 EPS and Q4 2025 earnings at $0.16 EPS.

Sensus Healthcare (NASDAQ:SRTS) last issued its quarterly earnings data on Wednesday, February 5th. The company reported $0.09 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.10 by ($0.01). Sensus Healthcare had a net margin of 15.90% and a return on equity of 12.60%.

SRTS has been the subject of several other research reports. Maxim Group boosted their price objective on shares of Sensus Healthcare from $12.00 to $14.00 and gave the stock a “buy” rating in a research report on Friday, November 15th. Lake Street Capital assumed coverage on Sensus Healthcare in a report on Friday, January 31st. They issued a “buy” rating and a $18.00 price objective for the company.

Sensus Healthcare Trading Down 2.3 %

Shares of NASDAQ SRTS opened at $5.93 on Tuesday. Sensus Healthcare has a 1-year low of $2.91 and a 1-year high of $9.33. The company has a 50-day moving average of $7.33 and a two-hundred day moving average of $6.89. The company has a market cap of $97.19 million, a PE ratio of 14.83 and a beta of 1.24.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of SRTS. Truvestments Capital LLC bought a new stake in Sensus Healthcare during the 3rd quarter worth about $32,000. IFP Advisors Inc acquired a new position in Sensus Healthcare during the fourth quarter valued at approximately $95,000. Cubist Systematic Strategies LLC acquired a new position in Sensus Healthcare during the second quarter valued at approximately $156,000. XTX Topco Ltd grew its stake in Sensus Healthcare by 76.0% in the third quarter. XTX Topco Ltd now owns 31,530 shares of the company’s stock valued at $183,000 after purchasing an additional 13,619 shares in the last quarter. Finally, Virtu Financial LLC acquired a new position in shares of Sensus Healthcare during the 4th quarter worth approximately $189,000. 25.30% of the stock is currently owned by institutional investors.

About Sensus Healthcare

Sensus Healthcare, Inc, a medical device company, manufactures and sells radiation therapy devices to healthcare providers worldwide. The company uses superficial radiation therapy, a low-energy X-ray technology in its portfolio of treatment devices. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers, including basal cell and squamous cell skin cancers, as well as other skin conditions, such as keloids; and SRT-100 Vision, which provides the user with a superficial radiation therapy-tailored treatment planning application that integrates an embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters.